…
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Journey Medical Corporation is a U.S.-focused specialty pharmaceutical company that develops, markets and distributes prescription dermatology treatments to dermatologists and other prescribers. Its long-term growth drivers include sustained demand for therapies addressing chronic and common skin conditions, expansion of its branded and in-licensed product portfolio, and targeted specialty sales and marketing efforts that may benefit recurring prescription patterns and market penetration.
Material risks include dependence on a limited portfolio, pricing and reimbursement pressure, competition from generics and larger dermatology firms, and execution and liquidity risks typical of smaller specialty pharmaceutical companies.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -11.37M | -14.61M | -3.63M | -29.57M | -42.36M |
| Net income | -11.43M | -14.67M | -3.85M | -29.63M | -43.99M |
| Selling general administrative | 44.37M | 40.20M | 48.06M | 59.47M | 39.83M |
| Gross profit | 36.68M | 35.26M | 52.52M | 42.89M | 31.05M |
| Reconciled depreciation | 4.35M | 3.52M | 4.26M | 4.37M | 2.56M |
| Ebit | -8.17M | -11.91M | -1.93M | -27.52M | -25.34M |
| Ebitda | -3.83M | -8.40M | 1.92M | -27.46M | -25.34M |
| Depreciation and amortization | 4.35M | 3.52M | 3.85M | 0.06M | 0.00M |
| Operating income | -8.17M | -13.68M | -2.07M | -27.52M | -25.34M |
| Other operating expenses | 70.03M | 69.81M | 81.25M | 101.19M | 88.47M |
| Interest expense | 3.70M | 2.70M | 1.70M | 2.02M | 7.03M |
| Tax provision | 0.06M | 0.06M | 0.11M | 0.06M | 1.63M |
| Interest income | 0.59M | 0.76M | 0.26M | 0.06M | 0.00M |
| Net interest income | -3.11M | -1.94M | -2.03M | -1.96M | -7.03M |
| Income tax expense | 0.06M | 0.06M | 0.22M | 0.06M | 1.63M |
| Total revenue | 61.86M | 56.13M | 79.18M | 73.67M | 63.13M |
| Total operating expenses | 44.85M | 48.93M | 54.59M | 70.41M | 56.39M |
| Cost of revenue | 25.18M | 20.88M | 26.66M | 30.77M | 32.08M |
| Total other income expense net | -3.20M | -0.93M | -1.56M | -2.05M | -17.02M |
| Net income from continuing ops | -11.43M | -14.67M | -12.35M | -29.63M | -43.99M |
| Net income applicable to common shares | - | - | - | -29.63M | -43.99M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 94.59M | 80.24M | 76.85M | 105.16M | 97.28M |
| Intangible assets | 27.61M | 31.86M | 20.29M | 27.20M | 12.55M |
| Other current assets | 3.38M | 3.21M | 3.59M | 3.31M | 2.44M |
| Total liab | 62.74M | 60.17M | 56.50M | 88.18M | 55.24M |
| Total stockholder equity | 31.85M | 20.07M | 20.35M | 16.98M | 42.04M |
| Other current liab | 27.96M | 18.36M | 20.37M | 27.23M | 4.51M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -98.46M | -87.03M | -72.36M | -68.50M | -38.87M |
| Other liab | - | - | - | - | 0.01M |
| Other assets | - | - | - | 0.10M | 0.15M |
| Cash | 24.09M | 20.30M | 27.44M | 32.00M | 49.08M |
| Total current liabilities | 37.44M | 35.17M | 41.87M | 66.83M | 51.61M |
| Current deferred revenue | - | -0.59M | 0.05M | - | 23.37M |
| Net debt | -23.97M | 5.40M | -9.71M | -9.04M | -48.17M |
| Short term debt | 0.10M | 0.71M | 3.10M | 3.03M | 0.91M |
| Short long term debt | - | - | - | 2.95M | 0.81M |
| Short long term debt total | 0.12M | 25.70M | 17.73M | 22.96M | 0.91M |
| Other stockholder equity | 130.31M | 107.09M | 92.70M | 85.48M | 80.92M |
| Property plant equipment | - | - | - | 0.19M | 0.09M |
| Total current assets | 66.87M | 48.18M | 56.45M | 77.68M | 84.49M |
| Net tangible assets | - | - | - | -10.21M | 29.49M |
| Net receivables | 29.78M | 10.23M | 15.22M | 28.21M | 23.11M |
| Long term debt | 25.28M | 24.88M | 14.62M | 19.83M | - |
| Inventory | 9.62M | 14.43M | 10.21M | 14.16M | 9.86M |
| Accounts payable | 9.31M | 16.05M | 18.34M | 36.57M | 22.81M |
| Non currrent assets other | - | - | 0.01M | 0.10M | 0.15M |
| Non current assets total | 27.72M | 32.06M | 20.39M | 27.48M | 12.79M |
| Capital lease obligations | 0.12M | 0.20M | 0.11M | 0.19M | 0.10M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -15.00M | -5.00M | -20.00M | -10.00M |
| Change to liabilities | - | - | - | 0.00M | 21.71M |
| Total cashflows from investing activities | - | -15.00M | -5.00M | - | -10.00M |
| Net borrowings | 15.73M | 16.63M | -4.45M | - | 5.05M |
| Total cash from financing activities | 16.23M | 16.99M | -4.80M | 16.46M | 53.02M |
| Change to operating activities | - | - | - | - | 0.78M |
| Net income | -11.43M | -14.67M | -3.85M | -29.63M | -43.99M |
| Change in cash | 3.79M | -7.13M | -4.56M | -17.08M | 40.84M |
| Begin period cash flow | 20.30M | 27.44M | 32.00M | 49.08M | 8.25M |
| End period cash flow | 24.09M | 20.30M | 27.44M | 32.00M | 49.08M |
| Total cash from operating activities | -12.44M | -9.13M | 5.24M | -13.53M | -2.18M |
| Issuance of capital stock | - | - | 4.49M | 0.00M | 51.50M |
| Depreciation | 4.72M | 3.42M | 3.85M | 4.37M | 2.56M |
| Other cashflows from investing activities | - | -15.00M | -5.00M | - | - |
| Change to inventory | 4.81M | -4.22M | 3.95M | 1.74M | -8.46M |
| Change to account receivables | -19.34M | 4.47M | 12.55M | -5.38M | 0.77M |
| Other cashflows from financing activities | -0.07M | 0.37M | -0.35M | 24.69M | 31.97M |
| Change to netincome | - | - | - | - | 21.97M |
| Capital expenditures | 0.00M | 15.00M | 5.00M | 0.00M | 10.00M |
| Change in working capital | -11.90M | -3.77M | -1.66M | 6.19M | 14.71M |
| Stock based compensation | 6.29M | 6.10M | 2.61M | 4.42M | 2.47M |
| Other non cash items | -0.12M | -0.21M | 4.29M | 1.12M | 20.51M |
| Free cash flow | -12.44M | -9.13M | 0.24M | -13.53M | -12.18M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DERM Journey Medical Corp |
-0.26 7.18% |
3.29 | - | 172.41 | 2.79 | 4.47 | 2.32 | 17.72 |
| MKKGY Merck KGaA ADR |
-0.68 2.09% |
31.83 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.38 1.77% |
21.79 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
9237 East Via de Ventura Blvd., Scottsdale, AZ, United States, 85258
480 434 6670
58
| Name | Title | Year Born |
|---|---|---|
| Dr. Lindsay Allan Rosenwald | Exec. Chairman | 1955 |
| Mr. Claude Maraoui | Founder, Pres, CEO & Director | 1967 |
| Mr. Ernest Robert De Paolantonio CPA, CPA, M.B.A., MBA | Chief Financial Officer | 1953 |
| Mr. Andrew J. Zwible | VP of Operations | NA |
| Mr. Ramsey Alloush | Gen. Counsel & Company Sec. | 1986 |
| Mr. Ernest Galvan | VP of Marketing & Strategy | 1962 |
| Mr. Robert Nevin | Chief Commercial Officer | 1968 |
| Robyn Hunter | Treasurer & Sec. | NA |
| Dr. Lindsay Allan Rosenwald | Executive Chairman | 1955 |
| Mr. Claude Maraoui | Founder, President, CEO & Director | 1967 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.